Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MIF | P14174 | 2/20 | 0.53 |
| ▸ | CA12 | O43570 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA9 | Q16790 | 1/20 | 0.40 |
| ▸ | DAO | P14920 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.34 |
| ▸ | CASP3 | P42574 | 3/20 | 0.33 |
| ▸ | CASP7 | P55210 | 2/20 | 0.33 |
| ▸ | PMM2 | O15305 | 3/20 | 0.33 |
| ▸ | MPI | P34949 | 3/20 | 0.33 |
| ▸ | PHOSPHO1 | Q8TCT1 | 3/20 | 0.33 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.33 |
| ▸ | G6PD | P11413 | 2/20 | 0.33 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1123066 | 0.72 | CASP3 (0.58) | CASP3PMM2MPIPHOSPHO1G6PD | |
| SCHEMBL8370722 | 0.70 | MIF (0.79) | MIFCASP3PMM2MPIPHOSPHO1 | |
| SCHEMBL17191872 | 0.67 | CA12 (0.40) | CA12CA1CA9 | |
| SCHEMBL11372514 | 0.62 | CYP1A2 (0.46) | MIFDAOCYP1A2CYP2A6 | |
| SCHEMBL8444760 | 0.62 | KAT2B (0.47) | CA12CA1CA9KAT2B | |
| SCHEMBL3576624 | 0.61 | CA12 (0.35) | MIFCA12CA1CA9DAO | |
| SCHEMBL20246530 | 0.60 | MIF (0.50) | MIFCA12CA1CA9CYP2A6 | |
| SCHEMBL6002962 | 0.60 | CYP1A2 (0.38) | MIFCYP1A2CYP2A6 | |
| SCHEMBL29908309 | 0.60 | CYP2A6 (0.42) | MIFCYP1A2CYP2A6 | |
| SCHEMBL787846 | 0.60 | CYP2A6 (0.42) | MIFCYP1A2CYP2A6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7674810-B2 | 1,1-dioxo-1H-1Λ6-benzo[d]isothiazol-3-yl)-4-hydroxy-1,5-dihydro-pyrrol-2-one inhibitors of HCV polymerase | ROCHE PALO ALTO LLC (US) | 2010-03-09 | — | — | US | disclosed |
| US-20060252785-A1 | Heterocyclic antiviral compounds | ROCHE PALO ALTO LLC | 2006-11-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060252785-A1 | Heterocyclic antiviral compounds | EIF2AK2, HAVCR2, POLR2E | MIF 2416/4885CA12 4693/4885CA1 4732/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.